• OPEN AN ACCOUNT
Indian Indices
Sensex
82,851.04 -823.88
( -0.98%)
Global Indices
Nasdaq
49,462.85 -679.56
(-1.36%)
Dow Jones
6,851.97 -110.50
(-1.59%)
Hang Seng
57,040.53 -599.31
(-1.04%)
Nikkei 225
10,413.72 -58.39
(-0.56%)
Forex
USD-INR
90.66 0.06
(0.07%)
EUR-INR
107.82 -0.02
(-0.02%)
GBP-INR
123.81 -0.01
(0.00%)
JPY-INR
0.59 0.01
(1.13%)

EQUITY - MARKET SCREENER

Ajanta Pharma Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
532331
INE031B01049
330.3875196
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJANTPHARM
38.28
36093.9
EPS(TTM)
Face Value()
Div & Yield %
75.48
2
0.97
 

Ashok Leyland gains after December sales jump 27% YoY to 21,533 units
Jan 01,2026

Total domestic sales climbed 26% YoY to 19,885 units during the month. Domestic sales of medium and heavy commercial vehicles (M&HCV) grew 29% to 13,553 units, while light commercial vehicle (LCV) sales rose 21% to 6,302 units in December 2025 over the year-ago period.

Including exports, M&HCV sales increased 29% to 14,830 units, while LCV sales rose 22% to 6,703 units during the month.

Ashok Leyland is engaged in the manufacture and sale of a wide range of commercial vehicles. The company also manufactures engines for industrial and marine applications, forgings, and castings.

Ashok Leyland reported a marginal rise in standalone net profit to Rs 771.06 crore in Q2 FY26, compared to Rs 770.10 crore posted in Q2 FY25. Revenue from operations jumped 9.34% year-on-year (YoY) to Rs 9,588.18 crore for the quarter ended 30 September 2025.